In vivo therapeutic success of microRNA-155 antagomir in a mouse model of pulmonary fibrosis induced by bleomycin
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: MicroRNAs (miRNAs) play critical regulatory roles in the pathogenesis of pulmonary fibrosis. The aim of this study was to explore whether miRNA antagomirs could serve as potential therapeutic agents in interstitial lung diseases. Methods: A mouse model of pulmonary fibrosis was established by intratracheal injection of bleomycin (BLM). Using microarray analysis, up-regulated miRNAs were identified during the development of pulmonary fibrosis. miR-155 was chosen as the candidate miRNA. Fifteen mice were then randomized into the following three groups: BLM + antagomiR-155 group, treated with BLM plus intravenously injected with antagomiR-155; BLM group, treated with intratracheal BLM plus phosphate-buffered saline (PBS); and a control group, treated with PBS only. Lung tissues were collected for histopathological analysis, hydroxyproline measurement, and Western blotting. Enzyme-linked immunosorbent assays were used for the measurement of cytokines associated with pulmonary fibrosis. Results: Histological changes and hydroxyproline levels induced by BLM were significantly inhibited by antagomiR-155. The levels of interleukin 4 (IL-4) and transforming growth factor-β (TGF-β) expression were increased after BLM treatment. However, miR-155 silencing decreased the expression of IL-4, TGF-β, and interferon-γ. TGF-β-activated kinase 1/mitogen-activated protein kinase kinase kinase 7 (MAP3K7)-binding protein 2 (TAB2) of the mitogen-activated protein kinase (MAPK) signaling pathway, was activated by BLM and inhibited by in vivo silencing of miR-155 via antagomiR-155. Conclusions: In vivo treatment with antagomiR-155 alleviated the pathological changes induced by BLM and may be a promising therapeutic strategy for pulmonary fibrosis.
Abstract
Background/Aims: MicroRNAs (miRNAs) play critical regulatory roles in the pathogenesis of pulmonary fibrosis. The aim of this study was to explore whether miRNA antagomirs could serve as potential therapeutic agents in interstitial lung diseases. Methods: A mouse model of pulmonary fibrosis was established by intratracheal injection of bleomycin (BLM). Using microarray analysis, up-regulated miRNAs were identified during the development of pulmonary fibrosis. miR-155 was chosen as the candidate miRNA. Fifteen mice were then randomized into the following three groups: BLM + antagomiR-155 group, treated with BLM plus intravenously injected with antagomiR-155; BLM group, treated with intratracheal BLM plus phosphate-buffered saline (PBS); and a control group, treated with PBS only. Lung tissues were collected for histopathological analysis, hydroxyproline measurement, and Western blotting. Enzyme-linked immunosorbent assays were used for the measurement of cytokines associated with pulmonary fibrosis. Results: Histological changes and hydroxyproline levels induced by BLM were significantly inhibited by antagomiR-155. The levels of interleukin 4 (IL-4) and transforming growth factor-β (TGF-β) expression were increased after BLM treatment. However, miR-155 silencing decreased the expression of IL-4, TGF-β, and interferon-γ. TGF-β-activated kinase 1/mitogen-activated protein kinase kinase kinase 7 (MAP3K7)-binding protein 2 (TAB2) of the mitogen-activated protein kinase (MAPK) signaling pathway, was activated by BLM and inhibited by in vivo silencing of miR-155 via antagomiR-155. Conclusions: In vivo treatment with antagomiR-155 alleviated the pathological changes induced by BLM and may be a promising therapeutic strategy for pulmonary fibrosis.
참고문헌 (38)
- Antoniou KM, "Interstitial lung disease", Eur Respir Rev, 23, pp.40~54 (2014)
- Tzilas V, "Prognostic factors in idiopathic pulmonary fibrosis", Am J Med Sci, 338, pp.481~485 (2009)
- Filipowicz W, "RNAi : the nuts and bolts of the RISC machine", Cell, 122, pp.17~20 (2005)
- Pandit KV, "MicroRNAs in idiopathic pulmonary fibrosis", Transl Res, 157, pp.191~199 (2011)
- Zhang S, "miR-30a as potential therapeutics by targeting TET1 through regulation of Drp-1promoter hydroxymethylation in idiopathic pulmonary fibrosis", Int J Mol Sci, 18, pp.E633~ (2017)
- Liu W, "Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in mice", Respir Res, 14, pp.101~ (2013)
- Ashcroft T, "Simple method of estimating severity of pulmonary fibrosis on a numerical scale", J Clin Pathol, 41, pp.467~470 (1988)
- Chang JT, "GATHER : a systems approach to interpreting genomic signatures", Bioinformatics, 22, pp.2926~2933 (2006)
- Kanehisa M, "KEGG for representation and analysis of molecular networks involving diseases and drugs", Nucleic Acids Res, 38(Database issue), pp.D355~D360 (2010)
- Wynn TA, "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases", J Clin Invest, 117, pp.524~529 (2007)
- Moeller A, "The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?", Int J Biochem Cell Biol, 40, pp.362~382 (2008)
- Kato M, "TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN", Nat Cell Biol, 11, pp.881~889 (2009)
- Ji J, "Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation", FEBS Lett, 583, pp.759~766 (2009)
- Xie T, "Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation", Physiol Genomics, 43, pp.479~487 (2011)
- Zhou S, "In vivo therapeutic success of microRNA-155 antagomir in a mouse model of lupus alveolar hemorrhage", Arthritis Rheumatol, 68, pp.953~964 (2016)
- Pottier N, "Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions", PLoS One, 4, pp.e6718~ (2009)
- Oak SR, "A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis", PLoS One, 6, pp.e21253~ (2011)
- Janssen HL, "Treatment of HCV infection by targeting microRNA", N Engl J Med, 368, pp.1685~1694 (2013)
- van Rooij E, "MicroRNA therapeutics for cardiovascular disease : opportunities and obstacles", Nat Rev Drug Discov, 11, pp.860~872 (2012)
- Lin CW, "MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1", Nat Commun, 4, pp.1877~ (2013)
- Brock M, "AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension", Eur Heart J, 35, pp.3203~3211 (2014)
- Jakubzick C, "Therapeutic targeting of IL-4-and IL-13-responsive cells in pulmonary fibrosis", Immunol Res, 30, pp.339~349 (2004)
- Gharaee-Kermani M, "Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors", J Biol Chem, 271, pp.17779~17784 (1996)
- Makhluf HA, "IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts", J Invest Dermatol, 107, pp.856~859 (1996)
- Gein SV, "Effect of rotation and immobilization stress on IL-1β, IL-2, IL-4, and IFN-γ production by splenocytes under opiate receptor blockade in vivo", Dokl Biol Sci, 454, pp.69~71 (2014)
- Wallace WA, "Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease", J Pathol, 187, pp.475~480 (1999)
- Lukacs NW, "Type 1", type 2 cytokine paradigm and the progression of pulmonary fibrosis, 2001, pp.120, 5S~8S
- Zhang YY, "Expression and clinical significance of miR-155 in peripheral blood CD4(+);T cells of patients with allergic asthma", Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 28, pp.540~543 (2012)
- Sabri A, "Association study of genes controlling IL-12-dependent IFN-γ immunity : STAT4 alleles increase risk of pulmonary tuberculosis in Morocco", J Infect Dis, 210, pp.611~618 (2014)
- Xi W, "Lack of microRNA-155ameliorates renal fibrosis by targeting PDE3A", TGF-β1, Cell Biol Int, pp.2018, 42[DOI]
- Malmhall C, "MicroRNA-155 is essential for T(H)2-mediated allergen-induced eosinophilic inflammation in the lung", J Allergy Clin Immunol, 133, pp.1429~1438 (2014)
- Fernandez IE, "The impact of TGF-β on lung fibrosis : from targeting to biomarkers", Proc Am Thorac Soc, 9, pp.111~116 (2012)
- Zhang D, "Synergistic protection of Schizandrin B and Glycyrrhizic acid against bleomycin-induced pulmonary fibrosis by inhibiting TGF-β1", Smad2 pathways and overexpression of NOX4, 2017, pp.48, 67~75
- Ono K, "A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-beta", Biochem Biophys Res Commun, 307, pp.332~337 (2003)
- Kim SI, "TGF-beta-activated kinase 1 and TAK1-binding protein 1 cooperate to mediate TGF-beta1-induced MKK3-p38MAPK activation and stimulation of type I collagen", Am J Physiol Renal Physiol, 292, pp.F1471~F1478 (2007)
- Xu C, "miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2", J Biol Chem, 288, pp.11074~11079 (2013)
- Zhu S, "The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α", Nat Med, 18, pp.1077~1086 (2012)
- Zhang D, "miR-155 regulates high glucose-induced cardiac fibrosis via the TGF-βsignaling pathway", Mol Biosyst, 13, pp.215~224 (2016)